Matteo here from Edinburgh. After my iGEM 2020 project, I founded CEXAL LTD to develop rapid molecular diagnostics for unmet needs. We use two engineered oligonucleotides to phenotypically and genotypically identify bacteria, validated across water, fuel, and urine. We are now translating this technology to blood for a point-of-care test for sepsis. Our core question is: what if the pathogen and correct antibiotic were known in 6 hours instead of 48? By combining our rapid phenotypic detection and antibiotic susceptibility testing technology, we deliver culture-like results within 6 hours—without waiting for blood cultures—enabling earlier targeted treatment and maximising patient survival.